North Valley Neurology & Sleep © All Rights Reserved.
Looking After Your Health
3815 E. Bell Rd. #2400
Phoenix, AZ 85032
Phone: (602) 482-2116
FAX: (602) 482-9563
We are moving to our new office!
Effective
June 1, 2010
3815 E. Bell Rd. #2400
Phoenix, AZ 85032
Effective
June 1, 2010
3815 E. Bell Rd. #2400
Phoenix, AZ 85032
Phone:
(602) 482-2116 Fax:
(602) 4829563
(602) 482-2116 Fax:
(602) 4829563
MULTIPLE SCLEROSIS RESEARCH Studies:
Subcutaneous Daclizumab every 4 weeks, versus Intramuscular Avonex every week. This study is for patients with relapsing forms of MS. All patients will receive active drug, no placebo is used in this study.
Ocrelizumab vs. Rebif for Relapsing Remitting Multiple Sclerosis. In this trial patients will receive either Ocrelizumab, or Rebif. All patients will receive active drug, no patients will receive placebo in this trial.
Ocrelizumab for Primary Progressive Multiple Sclerosis.
We have two other studies which may be enrolling in the near future. Please contact us for more information.
ALZHEIMERS DISEASE RESEARCH studies
Intravenous Bapineuzimab in non-carriers for APOE gene marker. In this study, patients with AD who are non-carriers will receive intravenous Bapineuzimab every 13 weeks.
Subcutaneous Daclizumab every 4 weeks, versus Intramuscular Avonex every week. This study is for patients with relapsing forms of MS. All patients will receive active drug, no placebo is used in this study.
Ocrelizumab vs. Rebif for Relapsing Remitting Multiple Sclerosis. In this trial patients will receive either Ocrelizumab, or Rebif. All patients will receive active drug, no patients will receive placebo in this trial.
Ocrelizumab for Primary Progressive Multiple Sclerosis.
We have two other studies which may be enrolling in the near future. Please contact us for more information.
ALZHEIMERS DISEASE RESEARCH studies
Intravenous Bapineuzimab in non-carriers for APOE gene marker. In this study, patients with AD who are non-carriers will receive intravenous Bapineuzimab every 13 weeks.